You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Responsible Drinking: Internet-based, Interactive Computer Tailored Intervention
SBC: Pro-Change Behavior Systems, Inc. Topic: NIAAADESCRIPTION (provided by applicant): Excessive alcohol use is associated with a range of serious and costly health, social, and economic consequences at the individual and societal level. This program of research serves as a venue by which to produce and test an innovative, science-based, and cost-effective means to intervene in a private, convenient, and individualized way with employed adults wh ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Training for Providers of an Evidence-Based AD Family Caregiver Intervention
SBC: HEALTHCARE INTERACTIVE, INC. Topic: NIADESCRIPTION (provided by applicant): Alzheimer's disease and related disorders (ADRD) constitute urgent challenges to U.S. healthcare systems as well as enormous burdens on society as a whole. Nearly 75 percent of the care for persons with ADRD is delivered at home, and family caregivers need ongoing support to manage the daunting physical and psychological demands of care. A 20+ year randomi ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
IMPROVING MANUFACTURING AND POTENCY OF CRYOPRESERVED MALARIA SPOROZOITE VACCINE
SBC: SANARIA INC. Topic: NIAIDDESCRIPTION (provided by applicant): The development of Sanaria's aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoite (SPZ)-based products has received international recognition during the past year, due principally to four findings: 1)PfSPZ Challenge (infectious PfSPZ) induced malaria in volunteers, 2) PfSPZ Vaccine (radiation attenuated PfSPZ) induced unprecedented levels ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Transgenic Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture
SBC: SANARIA INC. Topic: NIAIDDESCRIPTION (provided by applicant): An ideal tool for eliminating Plasmodium falciparum (Pf), the causative agent of 99% of all malaria deaths, would be a highly effective vaccine that prevents blood stage infection and thereby prevents both disease and transmission. Sanaria's goal is to develop and commercialize a Pf sporozoite (SPZ) vaccine that prevents Pf blood stage infection in gt 90% ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
N-Methanocarbathymidine (N-MCT) for the treatment of herpes and pox virus infecti
SBC: N&N Pharmaceuticals, Inc Topic: NIAIDDESCRIPTION (provided by applicant): Diseases associated with the Poxviridae (smallpox, vaccinia and cowpox viruses), and Herpesviridae (HSV-1, HSV-2, HSV-8, VZV, EBV) dsDNA viruses represent major worldwide public health problems. NandN Scientific, Inc. (NandN) is developing a first of its class broad-spectrum orally bioavailable antiviral drug, N- methanocarbathymidine (N-MCT), which has exhibit ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Development of Small Molecules as Antiprotozoal Agents
SBC: RADIX PHARMACEUTICALS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): The proposed research focuses on the development of novel therapeutic agents for the prevention and treatment of malaria caused by P. falciparum. A previous Phase I project has discovered novel molecules with potent antimalarial activity against both sensitive and multidrug resistant malaria strains in some in vitro and in vivo models. Lead compounds are low in ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Device to Improve Treatment of Colorectal CA using O2 Dependent Phosphorescence
SBC: SURGISENSE CORPORATION Topic: NCIDESCRIPTION (provided by applicant): Standard of care for surgical resection of rectal cancer is the performance of low anterior resection (LAR). After removal of the cancerous segment, a surgical stapler is used to restore continuity by creating an anastomosis between the resulting ends of disjointed bowel. Anastomotic leak is one of the most dreaded complications of colorectal surgery due to the ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Computerized Stage-Matched Intervention for Juvenile Offenders
SBC: Pro-Change Behavior Systems, Inc. Topic: NIDADESCRIPTION (provided by applicant): Juvenile crime imposes enormous costs on victims, on society, and on juvenile offenders themselves. However, research assessing the efficacy of interventions for young offenders show, on average, only small effects on recidivism, substance abuse, and other behavioral outcomes. A major problem with existing interventions is that they tend to neglect individual d ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Multimicrophone Adaptive Array Augmented with Visual Cueing
SBC: ADVANCED MEDICAL ELECTRONICS CORP Topic: NIDCDDESCRIPTION (provided by applicant): Advanced Medical Electronics Corporation (AME) proposes to develop a smartphone-based audiovisual array that enables hearing aid users to converse with multiple speakers in reverberant environments with significant speech babble noise where their hearing aids do not function well. The array will consist of a smartphone, a smartphone accessory, and a smartphone ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of
SBC: EPIVAX, INC. Topic: NIDDKDESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by optimizing the clinical delivery vehicle and treatment protocol, and by identifying correlates of efficacy in preparation for Phase 1 clinical trials. More than 13,000 children in the U.S. are diagnos ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health